The primary goal of this project is to develop novel and useful drugs for the control of pain and drug abuse. Recent years have seen a resurgence of opioid abuse, as well as the need for additional analgesics with limited abuse potential. Our objectives are to identify new receptor targets and lead drug candidates for further development. The project contains three major aims. The first focuses on heroin and morphine-6beta-glucuronide. Recent work indicates that these two agents act through a common receptor which is distinct from the mu receptor mediating morphine analgesia.
The first aim will explore the structure-activity relationships of both agonists and antagonists selective for this receptor based upon several lead compounds which we have identified.
The second aim addresses the role of the anti-opioid sigma1 receptor system in the modulation of opioid analgesia. Sigma1 agonists potently reverse the analgesic activity of a variety of classes of opioid analgesics while sigma1 antagonists potentiate opioid analgesia. The sigma1 receptor has recently been cloned and will serve as a basis for examining this system at the molecular level. The cloned receptor also can serve as a screening system for potential new drugs. The last aim involves further studies with a series of opioid analogs synthesized in the laboratory during the previous granting period. The recent identification of orphanin FQ/nociceptin (OFQ/N) has opened a new area of investigation. In addition to the major OFQ/N receptor, detailed binding studies have identified another subtype which binds traditional opiates quite poorly. However, we have identified an opioid derivative which labels this site with high affinity (Ki <5 nM) and which will serve as a lead compound in the design of more potent and selective alkaloid agonists and antagonists for this site. Finally, we will continue our efforts to synthesize radiolabeled affinity labels.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006241-10
Application #
2897809
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Rapaka, Rao
Project Start
1990-07-01
Project End
2003-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Le Rouzic, Valerie; Narayan, Ankita; Hunkle, Amanda et al. (2018) Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic. Anesth Analg :
Che, Tao; Majumdar, Susruta; Zaidi, Saheem A et al. (2018) Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell 172:55-67.e15
Baumann, Michael H; Majumdar, Susruta; Le Rouzic, Valerie et al. (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology 134:101-107
Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2018) Truncated ?-Opioid Receptors With 6 Transmembrane Domains Are Essential for Opioid Analgesia. Anesth Analg 126:1050-1057
Davis, Mellar P; Pasternak, Gavril; Behm, Bertrand (2018) Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 78:1211-1228
Marrone, Gina F; Le Rouzic, Valerie; Varadi, Andras et al. (2017) Genetic dissociation of morphine analgesia from hyperalgesia in mice. Psychopharmacology (Berl) 234:1891-1900
Pasternak, Gavril W (2017) Allosteric Modulation of Opioid G-Protein Coupled Receptors by Sigma1 Receptors. Handb Exp Pharmacol 244:163-175
Kim, Felix J; Pasternak, Gavril W (2017) Cloning the sigma2 receptor: Wandering 40 years to find an identity. Proc Natl Acad Sci U S A 114:6888-6890
Xu, Jin; Lu, Zhigang; Narayan, Ankita et al. (2017) Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine. J Clin Invest 127:1561-1573
Urai, Ákos; Váradi, András; Sz?cs, Levente et al. (2017) Synthesis and pharmacological evaluation of novel selective MOR agonist 6?-pyridinyl amidomorphines exhibiting long-lasting antinociception. Medchemcomm 8:152-157

Showing the most recent 10 out of 86 publications